Retatrutide, an investigational triple-hormone receptor agonist developed by Eli Lilly, significantly reduced breathing pauses in adults with moderate-to-severe obstructive sleep apnea and obesity over an 80-week trial period, according to data published in The New England Journal of Medicine.
In Plain English: The Clinical Takeaway
- What was tested: Retatrutide, a weekly injectable medication, was evaluated in two Phase 3 clinical trials for adults suffering from obstructive sleep apnea.
- The core finding: Across both trials, patients experienced substantial reductions in the number of breathing interruptions per hour compared to a placebo group, driven largely by significant overall weight loss.
- Safety profile: The most common adverse events were gastrointestinal, including diarrhea and nausea, which occurred more frequently at higher doses of the drug.
Phase 3 Clinical Trial Results in Non-Diabetic and Diabetic Cohorts
Led by Ronald Grunstein, an international research team evaluated the weekly injectable drug across 691 adult participants diagnosed with a body-mass index of 27 or higher alongside moderate-to-severe obstructive sleep apnea, defined as experiencing at least 15 breathing pauses per hour. The evaluation was split into two distinct Phase 3 studies, designated TRIUMPH-1-OSA and TRIUMPH-2-OSA, to assess efficacy in populations without and with type 2 diabetes.
The Most Powerful Obesity Drug Yet Has a Hidden Benefit—and It Happens While You Sleep | Ed Cara, GizmodoEli Lilly’s highly anticipated weight loss drug retatrutide may also do wonders for people’s restless nights, recent research shows.Last week, researchers published two… pic.twitter.com/RtXgaBsPNH
In the TRIUMPH-1-OSA study involving 243 participants without type 2 diabetes who had an average baseline index of 58.6 events per hour, the event rate dropped after 80 weeks by 22.9 events per hour at the 4 mg dose, 34.3 events at the 9 mg dose, and 31.7 events at the 12 mg dose. This contrasted with a reduction of 9.9 events per hour observed in the placebo group, yielding a placebokorrigregated decrease ranging from 13.0 to 24.4 events per hour. Meanwhile, the TRIUMPH-2-OSA study examined 448 participants with type 2 diabetes who started with an average baseline of 55.9 events per hour. In this cohort, reductions reached 19.2 events (4 mg), 24.7 events (9 mg), and 25.4 events (12 mg) per hour, compared to a drop of 10.3 events under placebo, translating to a placebokorrigregated decrease of 8.9 to 15.1 events per hour.
| Trial Cohort | Dosage | Baseline Events/Hour | Absolute Reduction | Placebo-Corrected Reduction |
|---|---|---|---|---|
| TRIUMPH-1-OSA (No Diabetes) | 4 mg | 58.6 | -22.9 | -13.0 |
| TRIUMPH-1-OSA (No Diabetes) | 9 mg | 58.6 | -34.3 | -24.4 |
| TRIUMPH-2-OSA (With Diabetes) | 4 mg | 55.9 | -19.2 | -8.9 |
| TRIUMPH-2-OSA (With Diabetes) | 12 mg | 55.9 | -25.4 | -15.1 |
Secondary Outcomes and Mechanistic Context
Beyond respiratory metrics, the trials tracked overall clinical remission rates and total body weight reduction. Remission or a mild form of the condition without tagesschläfrigkeit was achieved by 26.3 to 51.6 percent of non-diabetic subjects and 24.3 to 39.5 percent of those with type 2 diabetes, compared to 12.5 and 12.6 percent in the respective placebo arms. Weight loss reached 12.5 to 22.2 percent for participants without diabetes and 12.1 to 18.5 percent for those with diabetes, outperforming the placebo reductions of 4.8 and 5.6 percent.
Adverse events were concentrated primarily in the gastrointestinal tract. Diarrhea affected roughly 34 percent of patients on higher doses compared to 13 percent in the placebo group, while nausea was reported by 28 percent of high-dose recipients versus 8 percent receiving placebo. Grunstein noted that the observed therapeutic impact is likely a consequence of weight loss. The agent remains an investigational, unapproved therapeutic and is not a substitute for a CPAP therapy.
Contraindications & When to Consult a Doctor
Retatrutide remains an investigational, unapproved therapeutic agent and is currently undergoing clinical evaluation. It is not intended to replace standard mechanical interventions such as continuous positive airway pressure (CPAP) therapy.
References
- New England Journal of Medicine: Phase 3 Trials of Retatrutide in Obstructive Sleep Apnea (TRIUMPH-1-OSA and TRIUMPH-2-OSA)
- EM consulte: Reviews on Obstructive Sleep Apnea and Microvascular Complications in Diabetes
- Lifelines Cohort Study: Genetic Variants Associated with Sleep Duration and Glycemic Control
